Pioneering a Cure for HIV
Addimmune is Harnessing the Power of Gene Therapy to Create a World Without HIV
By developing a new, life-changing approach to HIV using gene therapy, Addimmune hopes to replace a lifelong treatment approach with the new business model of developing an affordable and effective cure.
The Future of Medicine
Addimmune is focused on creating long-term value for patients, society and investors by developing and testing a cutting-edge gene therapy to cure HIV. We believe our HIV cure clinical trial could lead to a drug that brings relief to one of society's worst epidemics.
HIV Cure Program Patents
Our HIV technologies are covered by an extensive patent portfolio. DLA Piper Global Law Firm and Snell and Wilmer serve as our patent counsel.
- 10,233,464
- 10,036,038
- 10,494,647
- 10,888,613
- 11,090,379
- 11,007,209
Addimmune Clinical Trial Progress
FEB - 2019
NIAID signs collaborative research agreement for HIV/AIDS cure strategy
MAY - 2019
HIV program granted a second patent for its unique molecule, methods, and cell process
APR - 2020
FDA granted Type-A meeting for HIV cure IND
AUG - 2020
FDA grants IND approval
OCT - 2020
HIV cure program Phase 1 begins (first patient enrolled)
NOV - 2020
HIV cure program second patient enrolled and first patient product complete
FEB - 2019
NIAID signs collaborative research agreement for HIV/AIDS cure strategy
MAY - 2019
HIV program granted a second patent for its unique molecule, methods, and cell process
APR - 2020
FDA granted Type-A meeting for HIV cure IND
AUG - 2020
FDA grants IND approval
OCT - 2020
HIV cure program Phase 1 begins (first patient enrolled)
NOV - 2020
HIV cure program second patient enrolled and first patient product complete
Clinical Trial Progress
APR - 2021
First product cleared for infusion
MAY - 2021
First patient infusion; no adverse events
JUL - 2021
HIV cure program initial efficacy markers
NOV - 2021
First safety report by DSMB; no safety concerns
AUG - 2022
Analytical Treatment Interruption (ATI)
NOV - 2022
Phase 1 Data was Published in Frontiers in Medicine Journal
Phase 1 HIV Clinical Trial Data Published in Frontiers in Medicine
Addimmune has hit two major benchmarks of our AGT103-T Phase 1 trial. Our clinical trial data was published in “Frontiers in Medicine”, a scientific journal focused on medical advancement.
Contact Us
We're happy to help!
Barry H. Wells, MD
Investor Relations
